Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Abbott Laboratories(ABT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABT
09/25/2026: ABT (1-star) is currently NOT-A-BUY. Pass it for now.
Abbott Laboratories is a leading global healthcare company focused on medical devices, diagnostics, nutrition, and generic pharmaceuticals. The company is well-regarded for its diversified business model, which provides financial stability, and its long track record of annual dividend increases, making it a staple for conservative income investors. Its primary growth opportunity lies in its innovative diabetes care technology and an expanding portfolio of digital health solutions. Key risks include intense competitive pricing, regulatory uncertainty, and the execution challenges inherent in maintaining large-scale medical technology manufacturing. Investors should monitor developments in CGM market share and the integration of new diagnostics technologies to assess future growth trajectories.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Abbott offers reliable, sustainable growth through its innovative medical technology pipeline. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive market sentiment and sustained earnings momentum. |
| Value investor | Mixed fit | The valuation often reflects its high-quality nature, which may not always offer a significant margin of safety. |
| Dividend investor | Strong fit | Over 50 years of consecutive dividend increases make it a hallmark for income-focused portfolios. |
| Low-risk investor | Strong fit | Abbott's diversified business and historical stability provide a lower-risk profile within the healthcare sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock is generally less volatile than the broader market, though healthcare regulation remains a factor. |
| Valuation risk | Medium | Investors should monitor valuation premiums relative to historical averages. |
| Competition risk (Medical Device Technology) | Medium / high | Rapid innovation from competitors can impact market share in key segments like diabetes care. |
| Business quality | Strong | Abbott's strong brand and portfolio diversification provide substantial franchise durability. |
| Dividend income | Strong | The company's long-term history of dividend growth provides high reliability for income. |
| Execution risk | Medium | Successfully launching complex medical technologies and integrating acquisitions is crucial for sustained performance. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 13.77% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 176.43B USD | Price to earnings Ratio 32.78 | 1Y Target Price 120.26 |
Price to earnings Ratio 32.78 | 1Y Target Price 120.26 | ||
Volume (30-day avg) 8.5M shares | Beta 0.59 | 52 Weeks Range 81.39 - 132.39 | Updated Date 09/26/2026 |
52 Weeks Range 81.39 - 132.39 | Updated Date 09/26/2026 | ||
Dividends yield (FY) 2.45% | Basic EPS (TTM) 3.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Medical Devices | Cardiovascular, diabetes, and neuromodulation devices. | This is a core growth driver focused on high-tech devices. |
| Diagnostics | Lab systems, rapid tests, and molecular diagnostics. | Provides stable, recurring revenue from test kits and equipment. |
| Established Pharmaceuticals | Branded generics in emerging markets. | Offers steady income from high-volume health needs. |
| Nutrition | Pediatric and adult nutritional products. | Provides a consistent, consumer-facing revenue base. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 32.78 | Forward PE 17.09 | Enterprise Value 206.08B | Price to Sales(TTM) 3.79 |
Enterprise Value 206.08B | Price to Sales(TTM) 3.79 | ||
Enterprise Value to Revenue 4.42 | Enterprise Value to EBITDA 17.58 | Shares Outstanding 1.74B | Shares Floating 1.72B |
Shares Outstanding 1.74B | Shares Floating 1.72B | ||
Percent Insiders 0.5 | Percent Institutions 81.82 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Abbott Laboratories
Exchange NYSE | Headquarters Abbott Park, IL, United States | ||
IPO Launch date 1978-01-13 | Executive Chairman & CEO Mr. Robert B. Ford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 122000 | Website https://www.abbott.com |
Full time employees 122000 | Website https://www.abbott.com | ||
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.